These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23021082)

  • 1. US Food and Drug Administration international collaborations for cellular therapy product regulation.
    Arcidiacono JA; Blair JW; Benton KA
    Stem Cell Res Ther; 2012 Sep; 3(5):38. PubMed ID: 23021082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. United States Food and Drug Administration Regulation of Gene and Cell Therapies.
    Bailey AM; Arcidiacono J; Benton KA; Taraporewala Z; Winitsky S
    Adv Exp Med Biol; 2015; 871():1-29. PubMed ID: 26374210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four Food and Drug Administration draft guidance documents and the REGROW Act: A litmus test for future changes in human cell- and tissue-based products regulatory policy in the United States?
    Yano K; Speidel AT; Yamato M
    J Tissue Eng Regen Med; 2018 Jul; 12(7):1579-1593. PubMed ID: 29702746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon.
    Mendicino M; Fan Y; Griffin D; Gunter KC; Nichols K
    Cytotherapy; 2019 Jul; 21(7):699-724. PubMed ID: 31196820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory considerations for pluripotent stem cell therapies.
    Carpenter MK
    Prog Brain Res; 2017; 230():151-163. PubMed ID: 28552227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International Harmonization for Cell and Gene Therapy Products.
    Arcidiacono J
    Adv Exp Med Biol; 2023; 1430():235-240. PubMed ID: 37526852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian network analysis of risk classification strategies in the regulation of cellular products.
    Jia G; Fu L; Wang L; Yao D; Cui Y
    Artif Intell Med; 2024 Sep; 155():102937. PubMed ID: 39137589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [International approaches to the regulation of cell therapy products].
    Piatigorskaia NV; Tulina MA; Aladysheva ZhI; Beregovykh VV
    Vestn Ross Akad Med Nauk; 2013; (8):4-8. PubMed ID: 24340637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory issues in cellular therapies.
    Gee AP
    Expert Opin Biol Ther; 2003 Jul; 3(4):537-40. PubMed ID: 12831359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Worldwide Overview of Regulatory Frameworks for Tissue-Based Products.
    Oberweis CV; Marchal JA; López-Ruiz E; Gálvez-Martín P
    Tissue Eng Part B Rev; 2020 Apr; 26(2):181-196. PubMed ID: 31910099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA faces regulatory challenges with new approaches to medicine.
    Roehr B
    BMJ; 2014 Feb; 348():g1530. PubMed ID: 24531207
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulatory issues in cellular therapies.
    Gee AP
    J Cell Biochem Suppl; 2002; 38():104-12. PubMed ID: 12046844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Institutional profile. The International Society for Cellular Therapy: evolving to meet the demands of the regenerative medicine industry.
    Maziarz RT; Arthurs J; Horwitz E
    Regen Med; 2011 Mar; 6(2):163-6. PubMed ID: 21391849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are the European Medicines Agency, US Food and Drug Administration, and Other International Regulators Talking to Each Other?
    Teixeira T; Kweder SL; Saint-Raymond A
    Clin Pharmacol Ther; 2020 Mar; 107(3):507-513. PubMed ID: 31449664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.
    O'Neill T; Miksad R; Miller D; Maloney L; John A; Hiller C; Hornberger J
    Value Health; 2019 Jul; 22(7):754-761. PubMed ID: 31277820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis.
    Knoepfler PS; Turner LG
    Regen Med; 2018 Jan; 13(1):19-27. PubMed ID: 29327974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerating the development of innovative cellular therapy products for the treatment of cancer.
    Stewart MD; Keane A; Butterfield LH; Levine BL; Thompson B; Xu Y; Ramsborg C; Lee A; Kalos M; Koerner C; Moore T; Markovic I; Lasiter L; Ibrahim R; Bluestone J; Sigal E; Allen J
    Cytotherapy; 2020 May; 22(5):239-246. PubMed ID: 32199724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.